Baxter International Inc. (BAX): Today's Featured Health Care Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Baxter International ( BAX) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 2.6%. By the end of trading, Baxter International fell $0.77 (-1.1%) to $72.38 on average volume. Throughout the day, 3,171,873 shares of Baxter International exchanged hands as compared to its average daily volume of 3,650,000 shares. The stock ranged in price between $72.34-$73.38 after having opened the day at $73.10 as compared to the previous trading day's close of $73.15. Other companies within the Health Care sector that declined today were: DARA Biosciences ( DARA), down 14.1%, Unilife Corporation ( UNIS), down 10.9%, Aoxing Pharmaceutical Company ( AXN), down 9.0% and 22nd Century Group ( XXII), down 7.3%.

Baxter International Inc. develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney diseases, trauma, and other chronic and acute medical conditions. Baxter International has a market cap of $39.4 billion and is part of the health services industry. Shares are up 5.2% year to date as of the close of trading on Monday. Currently there are 4 analysts that rate Baxter International a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Baxter International as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations, expanding profit margins, increase in stock price during the past year and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the positive front, GW Pharmaceuticals ( GWPH), up 32.2%, Revance Therapeutics ( RVNC), up 25.8%, Evoke Pharma ( EVOK), up 18.2% and Idera Pharmaceuticals ( IDRA), up 16.9% , were all gainers within the health care sector with Biogen Idec ( BIIB) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

Airlines Rebuke Trump Policy of Separating Children

Airlines Rebuke Trump Policy of Separating Children

Dow Fluctuates, Nasdaq Strikes Record High

Dow Fluctuates, Nasdaq Strikes Record High

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Deutsche Bank Fined $205 Million Over Currency-Trading Violations

Deutsche Bank Fined $205 Million Over Currency-Trading Violations

Instagram Launches New Longform Video Platform

Instagram Launches New Longform Video Platform